All News

Autologous

FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies
29 November 2023
FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies
FDA investigates T cell malignancy
Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization
24 August 2023
Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization
Cellares has secured $255 million
FDA Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma
23 August 2023
FDA Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma
The FDA has granted Orphan
FDA Clears Aspen Neuroscience’s Cell Therapy IND Application for Parkinson’s Disease
23 August 2023
FDA Clears Aspen Neuroscience’s Cell Therapy IND Application for Parkinson’s Disease
The FDA has cleared Aspen
POPULAR NEWS ITEMS
Image
4 December 2023

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Image
6 December 2023

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Image
5 December 2023

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome

Kyverna’s Series B Financing Round Extends to $145M
3 August 2023
Kyverna’s Series B Financing Round Extends to $145M
Kyverna Therapeutics has oversubscribed its
Mustang Bio Announces Amendment and Closing of Manufacturing Partnership with uBriGene (Boston)
1 August 2023
Mustang Bio Announces Amendment and Closing of Manufacturing Partnership with uBriGene (Boston)
Mustang Bio has announced the
Iovance Biotherapeutics Announces Positive Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
12 July 2023
Iovance Biotherapeutics Announces Positive Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
Iovance announced its positive regulatory
MaxCyte and Vittoria Biotherapeutics Partner to Propel Next-Generation Cellular Therapies through Strategic Platform License
11 July 2023
MaxCyte and Vittoria Biotherapeutics Partner to Propel Next-Generation Cellular Therapies through Strategic Platform License
MaxCyte and Vittoria have recently
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

20 Years of Advanced Therapies with David McCall: a Retrospective on Phacilitate’s Founding and Evolution of the Industry

Image

Oxford Biomedica Acquires ABL Europe from Institut Mérieux

Image

Texas Children’s Hospital First to Deliver a Novel Gene Therapy for Rett Syndrome